2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Review slidesets and expert analyses of key data from the 2021 Clinical Oncology Virtual Scientific Meeting!

Genitourinary Cancers

Capsule Summary Slidesets

Pembrolizumab plus axitinib continued to demonstrate superior efficacy compared with sunitinib monotherapy in patients with previously untreated advanced clear-cell RCC with a median follow-up of 42 months.

Released: June 11, 2021

With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.

Released: June 11, 2021

With a median follow-up of 5 years, pembrolizumab continued to show improved overall survival compared with investigator’s choice of chemotherapy in patients with recurrent advanced urothelial cancer on the KEYNOTE-045 trial.

Released: June 11, 2021

Exploratory analyses of the CheckMate 9ER trial suggested PFS benefit with nivolumab + cabozantinib vs sunitinib across assessed subgroups defined by baseline disease characteristics.

Released: June 6, 2021

In patients with metastatic castration-sensitive prostate cancer, the addition of abiraterone to standard of care, ADT with or without docetaxel, prolonged median radiographic PFS by more than 2 years.

Released: June 17, 2021

Updated safety analysis of EORTC GUCG 1333/PEACE-3 confirms that risk of fractures was well controlled in both treatment arms when patients with mCRPC received BPAs.

Released: June 15, 2021

In this phase III trial, addition of 177Lu-PSMA-617 to standard of care in men with previously treated PSMA-positive mCRPC prolonged OS and radiographic PFS vs standard of care alone.

Released: June 15, 2021

Results of the first interim analysis for this randomized, double-blind phase III trial demonstrated significantly improved DFS with adjuvant pembrolizumab in patients with clear-cell RCC following nephrectomy.

Released: June 11, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings